Comparative Pharmacology
Head-to-head clinical analysis: POKONZA versus SERNIVO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: POKONZA versus SERNIVO.
POKONZA vs SERNIVO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
POKONZA (ponazuril) is a triazine antiprotozoal agent that inhibits the mitochondrial electron transport chain at the cytochrome bc1 complex, disrupting the parasite's energy metabolism and leading to its death. It is active against apicomplexan parasites such as Toxoplasma gondii, Neospora caninum, and Sarcocystis neurona.
SERNIVO (clobetasol propionate) is a corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive effects through induction of phospholipase A2 inhibitory proteins, collectively called lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.
Intravenous: 0.1 mg/kg every 8 hours for 28 consecutive days per 6-week cycle.
Apply a thin layer to affected area twice daily for up to 2 weeks.
None Documented
None Documented
Terminal elimination half-life 12-15 hours; clinically significant for once-daily dosing with steady-state achieved in 3-5 days
Approximately 3 hours (parent drug); clinical duration extended via formulation.
Primarily renal excretion (70-80% unchanged drug); biliary/fecal elimination accounts for 15-20%
Primarily renal excretion of inactive metabolites; <5% unchanged. Minor biliary/fecal elimination.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid